NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup Analysis

Jonathan Strosberg1; Edward Wolin 2; Beth Chasen3; Matthew Kulke 4; David Bushnell5; Martin Caplin6; Richard Baum7; Pamela Kunz8; Timothy Hobday 9; Andrew Hendifar10; Kjell Öberg11; Maribel Lopera Sierra12; Dik Kwekkeboom 13; Philippe Ruszniewski 14; Eric Krenning13

1H. Lee Moffitt Cancer Center; 2Markey Cancer Center, University of Kentucky; 3The University of Texas MD Anderson Cancer Center; 4Dana-Faber Cancer Institute; 5University of Iowa; 6Royal Free Hospital; 7Zentralklinik, Bad Berka; 8Stanford University Medical Center; 9Mayo Clinic College of Medicine; 10Cedars Sinai Medical Center; 11Oncology; 12Advanced Accelerator Application Inc.; 13Erasmus Medical Center; 14Hopital Beaujon

Background: Therapeutic options for patients are currently limited with advanced midgut neuroendocrine tumors progressing on first-line somatostatin analog therapy.

Methods: NETTER-1 is the first phase III, randomized trial evaluating 177Lu-DOTA0-Tyr3-Octreotate (Lutathera®) in patients with progressive, somatostatin receptor positive midgut NETs. 230 patients were randomized to receive Lutathera 7.4 GBq every 8 weeks (x4 administrations) versus Octreotide LAR 60 mg every 4 weeks. The primary endpoint was PFS (RECIST 1.1). Secondary objectives included ORR, OS, toxicity, and quality of life (QoL) based upon EORTC QLQ-C30 and QLQ-G.I.NET21 questionnaires. Subgroup analysis of PFS was performed to assess impact of potential prognostic factors.

Results: Centrally confirmed disease progressions or deaths were 23 in the Lutathera arm and 68 in the Octreotide LAR 60 mg arm. The median PFS was not reached for Lutathera and was 8.4 months with control, p<0.0001, HR 0.21. At the time of the NDA/MAA submission, interim OS analysis (14 deaths in Lutathera group and 26 in control group; p=0.0043) suggested an improvement in OS. Subgroup analyses for PFS confirmed consistent benefits of Lutathera irrespective of stratification and prognostic factors including tumor grade, age, gender, tumor marker levels, and levels of radiotracer uptake. Grade 3 or 4 neutropenia, thrombocytopenia and lymphopenia occurred in 1%, 2% and 9% of patients in Lutathera arm vs. none in controls. Health related QoL surveys indicated a moderate improvement in the global health status in the Lutathera treatment arm, demonstrating that the treatment benefit of Lutathera is not offset by a negative impact on patient quality of life.

Presented at NANETS 2016
**Conclusion:** The phase III NETTER-1 trial provides evidence for a clinically meaningful and statistically significant increase in PFS, and suggests an OS benefit in patients with advanced midgut NETs treated with Lutathera. Subgroup analysis demonstrates consistent benefit across prognostic factors. The Lutathera safety and QoL profile was found to be favorable.

Presented at NANETS 2016